Skip to content

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Eli Lilly’s diabetes drug gets UK green light

Eli Lilly's diabetes drug Mounjaro has gained the approval of Britain's healthcare cost-effectiveness watchdog. IG financial analyst @Angeline Ong looks at why this is significant, post-Covid.

Video poster image

(Video Transcript)

Type 2 diabetes patients could benefit

Eli Lilly's diabetes drug Mounjaro is in focus as it gained the backing of Britain's health care cost effectiveness watchdog which said it would be a good option for patients with poorly controlled type 2 diabetes.

Now this is a really interesting space for drug makers and has been in focus in recent months because any drug related to obesity or diabetes and heart problems is seen as the new sort of revenue generators for these big pharma firms, of, course after the Covid revenue stream peters off.

Drug may soon be available from NHS

What's also interesting about this drug that is being marketed by Eli Lilly is that it has the potential to treat obesity. Now some 180,000 people could benefit from this new treatment in the UK and Diabetes UK alone estimates that more than five million people in the UK are living with diabetes.

So what's the next key date to look out for? Well, final guidance which is scheduled to be published on 11 October might mean we'll find out whether or not this drug will be made available in the UK's National Health Service within 90 days after that.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Equities
  • Indices
  • Forex
  • Commodities
website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.

" >


Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Sunday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.


For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.